Study Name:
IMPALA2

Purpose of Study:

To discover whether molgramostim (inhaled GM-CSF) is safe to take and can help to reduce the symptoms of (autoimmune pulmonary alveolar proteinosis ) aPAP.

Study Dates:
May 3, 2021 - June 30, 2024

Study Location:
Nationwide

Lead Institution:
Cincinnati Children's Hospital Medical Center

Funding Source:
Savara Inc.

Sponsors:

Savara Inc.

Contact:

Michele Rhee
512-614-1848
[email protected]

ClinicalTrails.gov Identifier:
NCT04544293

Register for Trial
Asthma Basics Workshop - National
, | Feb 21, 2024
Asthma Basics Workshop - National
, | Mar 20, 2024